Breaking Nigeria’s 70% Drug Import Reliance: Experts Demand Radical Executive Reforms
By: Manoah Kikekon
LAGOS, NIGERIA — Industry experts and stakeholders are calling for an urgent structural overhaul of Nigeria's local pharmaceutical framework to safeguard the nation’s healthcare sovereignty. Currently, Nigeria relies on foreign imports for over 70 percent of its essential medicines, leaving its population highly vulnerable to international supply chain shocks and currency volatility.
The urgent call to action took center stage at the 29th Annual National Conference of the Association of Industrial Pharmacists of Nigeria (NAIP). Leading industry figures warned that without decisive political will and rigorous operational execution, Nigeria's healthcare sector faces severe instability.
The domestic pharmaceutical industry is battling severe macroeconomic headwinds, including extreme foreign exchange (FX) volatility, soaring production overheads, and the skyrocketing cost of Active Pharmaceutical Ingredients (APIs) — the raw chemical materials needed to create finished medications.
In her keynote address, Dr. Nonye Onyewuenyi, a United States-based pharmaceutical scientist and Chief Executive Scientist Officer of Nolix Analytics, emphasized that Nigeria already has the foundational resources and human talent necessary to reverse this trend.
“We have the raw materials and the ambition, but what we lack is a deliberate policy,” Dr. Onyewuenyi declared. “It is unacceptable for a nation of over 200 million people with more than 200 registered pharmaceutical firms to still import over 70 percent of its drugs.”
Dr. Onyewuenyi called on the federal government to move past mere policy announcements. She urged the aggressive funding and implementation of the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) and the Renewed Hope Agenda.
The critique extended into executive corporate management, where traditional, slow-moving administrative systems were called out as outdated.
Mazi Sam I. Ohuabunwa, former President of the Pharmaceutical Society of Nigeria (PSN) and founding CEO of Neimeth International Pharmaceuticals Plc, argued that pharmaceutical companies must implement daily operational accountability to survive current market turbulence.
“Performance management is the heartbeat of corporate sustainability,” Ohuabunwa stated during an intensive training session. “It is not an HR yearly form; it is a daily commitment to ensuring our patients win and our business grows.”
Ohuabunwa urged corporate leaders to transition to high-frequency weekly performance metrics and continuous field supervision to flag operational risks early.
On the scientific front, domestic producers face significant limitations due to underfunded research laboratories and aging production infrastructure. To bridge this gap, Dr. Onyewuenyi hosted technical masterclasses introducing Quality by Design (QbD) frameworksa method that builds safety controls directly into the early chemical formulation stages of manufacturing.
Roadmap to Healthcare Sovereignty
70% Import Dependence, Fully fund the PVAC framework; build dedicated pharmaceutical parks. Self-sufficiency in critical drug categories.
High API Raw Material Costs, Introduce aggressive tax incentives for local chemical synthesis. Lower retail prices for essential medicines.
Outdated Corporate Culture, Adopt daily data-driven management tracking instead of annual evaluations. Increased operational agility and output.
Infrastructure Deficits, Scale university-to-industry R&D pipelines with NAFDAC and NIPRD.
Internationally compliant cGMP factories.
Both leaders strongly warned against compromising data or technical standards, reminding stakeholders that shortcuts in medical manufacturing directly endanger human lives.
“In pharma, we deal with lives,” Ohuabunwa warned. “You cannot ‘PIP’ [Performance Improvement Plan] your way out of falsified records or data integrity breaches.”
Reacting to the blueprints presented, the National Chairman of NAIP, Pharm. (Sir) Bankole Ezebuiro, commended the experts and assured attendees that the association would actively drive the implementation of these strategic proposals across the industrial sector.
By: Manoah Kikekon
LAGOS, NIGERIA — Industry experts and stakeholders are calling for an urgent structural overhaul of Nigeria's local pharmaceutical framework to safeguard the nation’s healthcare sovereignty. Currently, Nigeria relies on foreign imports for over 70 percent of its essential medicines, leaving its population highly vulnerable to international supply chain shocks and currency volatility.
The urgent call to action took center stage at the 29th Annual National Conference of the Association of Industrial Pharmacists of Nigeria (NAIP). Leading industry figures warned that without decisive political will and rigorous operational execution, Nigeria's healthcare sector faces severe instability.
The domestic pharmaceutical industry is battling severe macroeconomic headwinds, including extreme foreign exchange (FX) volatility, soaring production overheads, and the skyrocketing cost of Active Pharmaceutical Ingredients (APIs) — the raw chemical materials needed to create finished medications.
In her keynote address, Dr. Nonye Onyewuenyi, a United States-based pharmaceutical scientist and Chief Executive Scientist Officer of Nolix Analytics, emphasized that Nigeria already has the foundational resources and human talent necessary to reverse this trend.
“We have the raw materials and the ambition, but what we lack is a deliberate policy,” Dr. Onyewuenyi declared. “It is unacceptable for a nation of over 200 million people with more than 200 registered pharmaceutical firms to still import over 70 percent of its drugs.”
Dr. Onyewuenyi called on the federal government to move past mere policy announcements. She urged the aggressive funding and implementation of the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) and the Renewed Hope Agenda.
The critique extended into executive corporate management, where traditional, slow-moving administrative systems were called out as outdated.
Mazi Sam I. Ohuabunwa, former President of the Pharmaceutical Society of Nigeria (PSN) and founding CEO of Neimeth International Pharmaceuticals Plc, argued that pharmaceutical companies must implement daily operational accountability to survive current market turbulence.
“Performance management is the heartbeat of corporate sustainability,” Ohuabunwa stated during an intensive training session. “It is not an HR yearly form; it is a daily commitment to ensuring our patients win and our business grows.”
Ohuabunwa urged corporate leaders to transition to high-frequency weekly performance metrics and continuous field supervision to flag operational risks early.
On the scientific front, domestic producers face significant limitations due to underfunded research laboratories and aging production infrastructure. To bridge this gap, Dr. Onyewuenyi hosted technical masterclasses introducing Quality by Design (QbD) frameworksa method that builds safety controls directly into the early chemical formulation stages of manufacturing.
Roadmap to Healthcare Sovereignty
70% Import Dependence, Fully fund the PVAC framework; build dedicated pharmaceutical parks. Self-sufficiency in critical drug categories.
High API Raw Material Costs, Introduce aggressive tax incentives for local chemical synthesis. Lower retail prices for essential medicines.
Outdated Corporate Culture, Adopt daily data-driven management tracking instead of annual evaluations. Increased operational agility and output.
Infrastructure Deficits, Scale university-to-industry R&D pipelines with NAFDAC and NIPRD.
Internationally compliant cGMP factories.
Both leaders strongly warned against compromising data or technical standards, reminding stakeholders that shortcuts in medical manufacturing directly endanger human lives.
“In pharma, we deal with lives,” Ohuabunwa warned. “You cannot ‘PIP’ [Performance Improvement Plan] your way out of falsified records or data integrity breaches.”
Reacting to the blueprints presented, the National Chairman of NAIP, Pharm. (Sir) Bankole Ezebuiro, commended the experts and assured attendees that the association would actively drive the implementation of these strategic proposals across the industrial sector.